Science Daily

Study finds new blood test predicts prognosis for advanced prostate cancer patients

A new study found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses. Published in Nature Communications, a new study ...
ascopubs.org

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial A total of 121 patients ...
EurekAlert!

Results from CARMEN-LC03 phase 3 study of tusamitamab ravtansine vs. docetaxel in previously treated advanced non-squamous NSCLC presented at WCLC 2024

(San Diego, Calif.--September 10, 2024, 10:35 a.m. PCT) A phase 3 study comparing tusamitamab ravtansine with docetaxel in patients with advanced non-squamous non-small cell lung cancer (NSCLC) ...
ascopubs.org

Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC).

Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment. Safety, tolerability and efficacy ...